Cycuria Therapeutics

Cycuria Therapeutics is a private, preclinical-stage biotech based in Graz, Austria, developing engineered biologic therapies for hard-to-treat cancers, with an initial focus on acute myeloid leukemia (AML). The company's proprietary platform aims to create first-in-class therapies that specifically eradicate leukemic stem cells, a key driver of relapse, while minimizing toxicity to healthy hematopoiesis. Led by a team with expertise in protein engineering and hemato-oncology, Cycuria is advancing a novel approach based on lymphotoxin-alpha biology, as evidenced by recent promising preclinical publications. The company is positioned to address a large market with high unmet need, particularly in older AML patients who cannot tolerate intensive standard therapies.

Proprietary platform for engineering protein-based biologics (centered on lymphotoxin-alpha biology) designed to directly target and eradicate leukemic stem cells while preserving healthy hematopoiesis.

Cycuria competes in the crowded and rapidly evolving AML therapeutics market, which includes approved FLT3 inhibitors (gilteritinib), IDH inhibitors (ivosidenib), BCL-2 inhibitors (venetoclax), and emerging modalities like bispecific antibodies (e.g., flotetuzumab) and CAR-T therapies. Its differentiation hinges on its unique stem-cell-targeting mechanism aimed at preventing relapse, a challenge not fully addressed by current standards of care.